HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
Titel:
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
Auteur:
Llombart-Cussac, Antonio Cortés, Javier Paré, Laia Galván, Patricia Bermejo, Begoña Martínez, Noelia Vidal, Maria Pernas, Sònia López, Rafael Muñoz, Montserrat Nuciforo, Paolo Morales, Serafín Oliveira, Mafalda de la Peña, Lorena Peláez, Alexandra Prat, Aleix